Formulary guidance and transparency from P&T to point of care

Perspectives on 2017 Drug Pipelines

Posted by Matt Breese on Jan 10, 2017

Find me on:

Perspectives on 2017 Drug Pipelines.png

In 2016, the number of new drugs approved by the FDA significantly decreased from previous years. 2017 will be an important year to watch as products make it from the late-phase pipeline to approval. In order to remain competitive, pharma companies must keep an eye on the market share protection and acquisition activity that impacts the franchise and disease area portfolios of other companies.

Pharma manufacturers must continually monitor the drug pipeline to assess their financial risk. In addition, payers need to be aware of what's coming in order to establish coverage precedents for new drugs and groups of products. Prescribers also need to be aware of new products to understand the clinical and financial benefits to patients.

2017 Drug Sales Forecast

The graphic below, from CPhi.CN, depicts the 2017 global pharmaceutical market forecast. According to the forecast, “Humira will top again with nearly USD 17.6 billion sales in 2017, however, the marketing of Amgen’s Amjevita, a biosimilar of Humira that has been approved by FDA in 2018, will inevitably have an impact on Humira.”

Top 10 Drugs by 2017 Sales.png
The Race for Immunology Products

While current drug sales remain strong, the pharmaceutical industry is racing to develop new cancer treatments and immunology products. Specifically, “focus is on the industry’s neck-and-neck race to market the first chimeric antigen receptor T-cell (CAR-T) therapy,” according to Pharma Exec. In addition, the industry is seeing a transition from small molecule drugs to biological drugs and complex treatments.

Top Product Launches

The pharmaceutical industry is also seeing substantial research and development in the area of biosimilars. There are many biosimilars in the pipeline set to compete with major blockbusters. For example, “The multiple sclerosis drug Ocrevus under Roche, and the IL-4/IL-13 blocker Dupilumab under Sanofi will be the potential blockbuster products, according to CPhi.CN. ” The graph below, from CPhi.CN, shows the ten most anticipated products to launch 2017.

Top Drug Launches in 2017.png

Drug pipelines represent the future of the pharmaceutical industry and healthcare. Monitoring the pipeline can reveal the strength of pharma companies in the long-term as well as the strength of specific classes. To stay up to date on the latest industry news, view the FDA decision calendar.

MMIT Network continually analyzes the drug pipeline to focus our formulary/policy collection and assessment resources better in specific areas of the market that will have the most impact to pharma, payers and prescribers.

Subscribe to the MMIT blog for more pharma, provider, and payer perspectives on key topics that affect the healthcare network.

Subscribe for Weekly Perspectives

Topics: Industry Trends, Branding & Marketing